HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ruth Tal-Singer Selected Research

Emphysema

4/2021Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD.
1/2021Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort.
1/2021Relationship between Emphysema Progression at CT and Mortality in Ever-Smokers: Results from the COPDGene and ECLIPSE Cohorts.
1/2020Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk.
11/2019End-product of fibrinogen is elevated in emphysematous chronic obstructive pulmonary disease and is predictive of mortality in the ECLIPSE cohort.
4/2019Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients.
1/2018Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype.
1/2017Multiple biomarkers predict disease severity, progression and mortality in COPD.
10/2016Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study.
1/2016Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ruth Tal-Singer Research Topics

Disease

124Chronic Obstructive Pulmonary Disease (COPD)
12/2023 - 02/2008
29Emphysema
04/2021 - 06/2010
25Inflammation (Inflammations)
01/2023 - 05/2005
8Disease Progression
11/2021 - 10/2012
5Lung Diseases (Lung Disease)
04/2022 - 02/2010
4Obstructive Lung Diseases (Obstructive Lung Disease)
01/2023 - 03/2012
4Cardiovascular Diseases (Cardiovascular Disease)
01/2023 - 07/2013
4Atherosclerosis
01/2018 - 01/2012
3Pneumonia (Pneumonitis)
07/2021 - 12/2017
3Asthma (Bronchial Asthma)
01/2021 - 01/2017
3Cachexia
05/2020 - 08/2012
3Dyspnea (Shortness of Breath)
01/2018 - 06/2010
2Respiratory Tract Infections (Respiratory Tract Infection)
11/2023 - 01/2021
2Weight Loss (Weight Reduction)
12/2021 - 05/2020
2Chronic Bronchitis
07/2021 - 07/2013
1COVID-19
11/2023
1Hypoxia (Hypoxemia)
01/2023
1Muscle Weakness
01/2023
1Pathologic Processes
11/2020
1Fibrosis (Cirrhosis)
07/2020
1Anorexia
05/2020
1Anemia
05/2020
1Fatigue
05/2020
1Hypertension (High Blood Pressure)
01/2020
1Arteritis
01/2018
1Overweight
03/2017

Drug/Important Bio-Agent (IBA)

81Biomarkers (Surrogate Marker)IBA
01/2023 - 01/2010
24GoldIBA
01/2023 - 06/2010
20Fibrinogen (Factor I)FDA Link
07/2021 - 11/2011
12Proteins (Proteins, Gene)FDA Link
12/2021 - 06/2011
11Bronchodilator Agents (Bronchodilators)IBA
12/2023 - 02/2008
7Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA
01/2018 - 03/2011
616S Ribosomal RNAIBA
01/2021 - 04/2016
5danirixinIBA
10/2021 - 01/2017
5C-Reactive ProteinIBA
07/2021 - 12/2012
5Adrenal Cortex Hormones (Corticosteroids)IBA
01/2021 - 06/2008
5p38 Mitogen-Activated Protein KinasesIBA
01/2018 - 01/2010
4Oxygen (Dioxygen)IBA
01/2023 - 06/2010
4Receptor for Advanced Glycation End ProductsIBA
04/2021 - 10/2013
4Interleukin-8 (Interleukin 8)IBA
01/2018 - 09/2013
3Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
12/2020 - 01/2017
3Interleukin-8B ReceptorsIBA
06/2020 - 05/2013
3ElastinIBA
11/2019 - 01/2016
3Interleukin-6 (Interleukin 6)IBA
01/2018 - 11/2011
3Fluticasone (Cutivate)FDA LinkGeneric
01/2016 - 06/2008
3OzoneIBA
08/2011 - 05/2005
2Volatile Organic CompoundsIBA
10/2021 - 02/2010
2FibrinIBA
11/2020 - 11/2019
2von Willebrand FactorIBA
07/2020 - 01/2020
26- (5- ((cyclopropylamino)carbonyl)- 3- fluoro- 2- methylphenyl)- N- (2,2- dimethylprpyl)- 3- pyridinecarboxamideIBA
01/2018 - 03/2012
2SteroidsIBA
01/2018 - 01/2016
2SmokeIBA
03/2016 - 07/2014
2Messenger RNA (mRNA)IBA
01/2016 - 04/2012
2CalciumIBA
01/2016 - 08/2014
2dilmapimodIBA
02/2015 - 01/2010
2Glycine (Aminoacetic Acid)FDA LinkGeneric
07/2014 - 08/2012
2GSK573719IBA
07/2013 - 02/2013
2SB 656933IBA
05/2013 - 08/2011
2Glutamine (L-Glutamine)FDA Link
10/2012 - 08/2012
2nasIBA
02/2012 - 03/2011
2ChemokinesIBA
08/2011 - 05/2011
1AerosolsIBA
11/2023
1GSK2881078IBA
01/2023
1Antiviral Agents (Antivirals)IBA
01/2023
1Androgen Receptors (Androgen Receptor)IBA
01/2023
1Testosterone (Sustanon)FDA Link
01/2023
1Nasal SpraysIBA
01/2023
1RNA (Ribonucleic Acid)IBA
01/2022
1Biological FactorsIBA
07/2021
1CytokinesIBA
01/2021
1Immunoglobulin E (IgE)IBA
01/2021
1Anti-Bacterial Agents (Antibiotics)IBA
01/2021
1PalmitatesIBA
11/2020
1HomocysteineIBA
11/2020
1Butyrates (Butyrate)IBA
11/2020
1Collagen Type VIIBA
07/2020
1endotrophinIBA
07/2020
1Hormones (Hormone)IBA
07/2020
1Peptides (Polypeptides)IBA
07/2020
1Indicators and Reagents (Reagents)IBA
07/2020
1IronIBA
05/2020
1Hemoglobins (Hemoglobin)IBA
05/2020
1Heme (Haem)IBA
05/2020
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2020
1Myeloblastin (Proteinase 3)IBA
11/2019
1Leukocyte Elastase (Neutrophil Elastase)IBA
11/2019
1EnzymesIBA
11/2019
1Cathepsin GIBA
11/2019
1Collagen Type IV (Type IV Collagen)IBA
04/2019
1type IV collagen alpha3 chain (Goodpasture antigen)IBA
04/2019
1Epoxide HydrolasesIBA
03/2017
1AcidsIBA
03/2017
1BradykininIBA
03/2017
1N- ((4- cyano- 2- (trifluoromethyl)phenyl)methyl)- 3- ((4- methyl- 6- (methylamino)- 1,3,5- triazin- 2- yl)amino)cyclohexanecarboxamideIBA
03/2017
1Fluconazole (Zonal)FDA LinkGeneric
03/2017

Therapy/Procedure

15Therapeutics
01/2023 - 01/2012
3Nebulizers and Vaporizers (Inhaler)
11/2023 - 01/2019
1Surgical Instruments (Clip)
01/2021
1Length of Stay
01/2020
1Intra-Arterial Infusions
03/2017